01.05.2016 | ICS congress 2015 | Sonderheft 2/2016
Resectability of rectal cancer after neoadjuvant treatment – current status
- Zeitschrift:
- European Surgery > Sonderheft 2/2016
- Autoren:
- MD PhD M. Sabol, R. Donát, P. Chvalný, J. Palaj, D. Dyttert, P. Mračna, Š. Durdík
Wichtige Hinweise
The supplement is dedicated to Jubilee World congress of International College of Surgeons 2015.
The publishing was sponsored by the Ministry of Health of the Czech Republic.
Abstract
Background
The purpose of the study was to compare our experience to recent trends of multimodal treatment of patients with locally advanced rectal cancer.
Patients and methods
209 patients with histologically proven adenocarcinoma of the rectum were treated for 3 years by a multimodal approach in a single center. Patients were evaluated for clinical and pathologic response. The type of surgical procedure and the number of retrieved lymph nodes and postoperative complications were recorded.
Results
Neoadjuvant Chemoradiotherapy (CRT) had a downstaging effect in more than half of our patients (50.61 %), and about one quarter of them achieved a complete pathologic response (22.22 %).
Conclusions
Preoperative CRT produced an encouraging down-staging effect with acceptable toxicity and perioperative complications.